CONTROLLED DRUG DELIVERY OCULAR IMPLANTS AND METHODS OF USING SAME

• US 20180177633A1
• Filed: 02/20/2018
• Published: 06/28/2018
• Est. Priority Date: 03/15/2013
• Status: Active Grant

• Current Assignee: DOSE Medical Corporation (Glaukos Corporation)
• Original Assignee: DOSE Medical Corporation (Glaukos Corporation)
• Inventors: Haffner, David S., Burns, Thomas W., Heitzmann, Harold A., Curry, Kenneth M.
• Granted Patent: US 11,253,394 B2
• Time in Patent Office: Days
• CPC Class Codes: A61F 2250/0067 Means for introducing or releasing pharmaceutical products into the body
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61F 9/00781 Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment drainage implants in general A61M27/002

Abstract

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Claims

1. A drug delivery ocular implant comprising:

an outer shell having a proximal end, a distal end, said outer shell being shaped to define an interior lumen;

at least a first active drug positioned within said interior lumen;

a cap configured for reversible interaction with the proximal end of said outer shell,

wherein said cap comprises at least one aperture;

a membrane positioned between said cap and said proximal end of of said outer shell,

wherein said membrane is permeable to said at least a first active drug,

wherein upon placement of the cap over the proximal end of the outer shell, said membrane is retained between said cap and said proximal end,

wherein said membrane occludes said at least one aperture, such that elution of said at least a first active drug occurs only through said membrane; and

a retention protrusion on the distal end of said outer shell, wherin said retention protrusion is configured to anchor the ocular implant at a target tissue site.